Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adalimumab biosimilar - LG Chem

Next Previous
Drug Profile

Adalimumab biosimilar - LG Chem

Alternative Names: LBAL; Xelenka

Latest Information Update: 12 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem; Mochida Pharmaceutical
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Registered Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Uveitis

Most Recent Events

  • 25 Nov 2021 Mochida Pharmaceuticals enter into a distribution and marketing agreement with AYUMI Pharmaceutical for adalimumab biosimilar in Japan
  • 25 Nov 2021 Launched for Rheumatoid arthritis in Japan (SC)
  • 06 Apr 2021 No development reported - Phase-III for Rheumatoid arthritis (Treatment-experienced; Adjunctive treatment) in South Korea and Japan (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top